These results support the continued recommendation of alectinib as one of the standard first-line therapeutic options for ALK-naïve ALK-positive advanced NSCLC even if lorlatinib becomes available for ALK-naïve patients. This evidence concerns the gene ALK and non-small cell lung carcinoma.